Company Filing History:
Years Active: 2017
Title: Jae Hui Been: Innovator in Antiangiogenic and Anticancer Therapeutics
Introduction
Jae Hui Been is a notable inventor based in Daegu, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in developing compounds that target angiogenesis and cancer growth.
Latest Patents
Jae Hui Been holds a patent for an amidopyridinol derivative or a pharmaceutically acceptable salt thereof. This invention includes a pharmaceutical composition that demonstrates an antiangiogenic effect in a chorioallantoic membrane model. The compound is useful for preventing or treating diseases associated with angiogenesis and has shown a colitis-inhibitory effect in models of inflammatory bowel diseases. Furthermore, it inhibits angiogenesis and tumor growth in lung cancer models, making it a promising candidate for cancer treatment.
Career Highlights
Throughout his career, Jae Hui Been has worked with the Research Cooperation Foundation of Yeungnam University and the Industry Academic Cooperation Foundation of Yeungnam University. His work has focused on innovative solutions in the pharmaceutical industry, particularly in the development of therapeutic agents.
Collaborations
Jae Hui Been has collaborated with notable colleagues, including Byeong Seon Jeong and Jung Ae Kim. Their combined efforts have contributed to advancements in the field of cancer research and treatment.
Conclusion
Jae Hui Been's innovative work in developing antiangiogenic and anticancer therapeutics highlights his significant role in pharmaceutical research. His contributions are paving the way for new treatments that could improve patient outcomes in various diseases.